Perspective Therapeutics, Inc. Announces Acceptance of Updated Data for [212Pb]VMT-α-NET Program at ESMO Congress 2025

Perspective Therapeutics to present updated data on [212Pb]VMT-α-NET program at ESMO Congress 2025 in Berlin.

Quiver AI Summary

Perspective Therapeutics, Inc. announced that updated data from its [212Pb]VMT-α-NET program will be presented at the ESMO Congress 2025 in Berlin from October 17 to 21, 2025. The presentation will, led by Thorvardur Halfdanarson from the Mayo Clinic, focus on targeted alpha-particle therapy for advanced somatostatin receptor 2 positive neuroendocrine tumors, highlighting safety and preliminary efficacy from ongoing clinical trials. The company is conducting a multi-center, open-label, dose-escalation study to treat patients with advanced SSTR2-positive tumors, building on previous interim findings. Perspective is a radiopharmaceutical company utilizing the alpha-emitting isotope 212Pb to develop targeted cancer therapies and complementary imaging diagnostics aimed at personalizing treatment and enhancing patient outcomes.

Potential Positives

• Updated data on the [212Pb]VMT-α-NET program will be presented at the prestigious European Society of Medical Oncology (ESMO) Congress 2025, enhancing the company's visibility in the oncology field.
• The program focuses on advanced treatment for SSTR2+ neuroendocrine tumors, potentially expanding the company's therapeutic impact and market reach.
• Interim data from the ongoing clinical trial indicate continued patient enrollment and extended follow-up, suggesting promising developments in the company's treatment efficacy.
• The company is developing complementary imaging diagnostics, which supports a "theranostic" approach, potentially leading to personalized treatment options and improved patient outcomes.

Potential Negatives

• Presentation of interim data at a major oncology congress may raise concerns about the maturity and robustness of the study, potentially affecting investor confidence.
• The mention of a reopening of Cohort 2 in August 2024 might imply challenges or delays in patient enrollment or study progression.
• The forward-looking statements caution against placing undue reliance on the company's projections, which could create uncertainty among stakeholders regarding future performance and prospects.

FAQ

What is the [212Pb]VMT-α-NET program?

The [212Pb]VMT-α-NET program targets SSTR2-positive neuroendocrine tumors using targeted alpha-particle therapy developed by Perspective Therapeutics.

When will the updated data be presented at the ESMO Congress?

The updated data will be presented during the ESMO Congress on October 20, 2025, at 9:00 am CEST.

Who will present the [212Pb]VMT-α-NET data?

Thorvardur Halfdanarson from the Mayo Clinic Comprehensive Cancer Center will present the [212Pb]VMT-α-NET data.

What is the aim of the [212Pb]VMT-α-NET clinical study?

The study aims to evaluate the safety and efficacy of [212Pb]VMT-α-NET in patients with advanced SSTR2-positive tumors.

How can I learn more about Perspective Therapeutics?

You can visit Perspective Therapeutics' official website at www.perspectivetherapeutics.com for more information.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$CATX Insider Trading Activity

$CATX insiders have traded $CATX stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $CATX stock by insiders over the last 6 months:

• ROBERT F III WILLIAMSON has made 2 purchases buying 60,337 shares for an estimated $132,151 and 0 sales.
• JUAN GRAHAM (Chief Financial Officer) purchased 33,333 shares for an estimated $74,945
• JOHAN M. SPOOR (Chief Executive Officer) has made 2 purchases buying 26,676 shares for an estimated $59,672 and 0 sales.
• LORI A WOODS purchased 23,475 shares for an estimated $49,999

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$CATX Hedge Fund Activity

We have seen 2 institutional investors add shares of $CATX stock to their portfolio, and 0 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• VESTOR CAPITAL, LLC added 974,720 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,076,153
• PORTLAND INVESTMENT COUNSEL INC. added 40,000 shares (+26.7%) to their portfolio in Q1 2025, for an estimated $85,200

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CATX Analyst Ratings

Wall Street analysts have issued reports on $CATX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

• B. Riley Securities issued a "Buy" rating on 06/23/2025
• Wedbush issued a "Outperform" rating on 06/23/2025
• RBC Capital issued a "Outperform" rating on 06/03/2025
• Truist Securities issued a "Buy" rating on 05/14/2025
• HC Wainwright & Co. issued a "Buy" rating on 03/31/2025
• Scotiabank issued a "Sector Outperform" rating on 03/07/2025

To track analyst ratings and price targets for $CATX, check out Quiver Quantitative's $CATX forecast page.

$CATX Price Targets

Multiple analysts have issued price targets for $CATX recently. We have seen 7 analysts offer price targets for $CATX in the last 6 months, with a median target of $12.0.

Here are some recent targets:

• Yuan Zhi from B. Riley Securities set a target price of $12.0 on 06/23/2025
• David Nierengarten from Wedbush set a target price of $11.0 on 06/23/2025
• Leonid Timashev from RBC Capital set a target price of $16.0 on 06/03/2025
• Nicole Germino from Truist Securities set a target price of $8.0 on 05/14/2025
• Robert Burns from HC Wainwright & Co. set a target price of $10.0 on 03/31/2025
• Louise Chen from Scotiabank set a target price of $15.0 on 03/07/2025

Full Release

SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) --

Perspective Therapeutics, Inc.

(“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [

²¹²

Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2025 taking place October 17 to 21, 2025 in Berlin, Germany. ESMO plans to release further details for regular abstracts on October 13, 2025.

About [



²¹²



Pb]VMT-α-NET



Perspective designed [

²¹²

Pb]VMT-α-NET to target and deliver

²¹²

Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier

NCT05636618

) of [

²¹²

Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (

ASCO

) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope

²¹²

Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary

²¹²

Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.

For more information, please visit the Company's website at

www.perspectivetherapeutics.com

.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company’s plans and the expected timing for the release of additional data from its clinical programs; the ability of the Company's proprietary technology utilizing the alpha emitting isotope

²¹²

Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moieties provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary

²¹²

Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements.  These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:



Annie J. Cheng, CFA



ir@perspectivetherapeutics.com

Russo Partners, LLC



Nic Johnson



PerspectiveIR@russopr.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.